ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Geriatric Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

12,220Medicare Part D Prescriptions Filled, Including Refills

Rank: 6 out of 29

$625K Total Retail Price of All Prescriptions

Rank: 9 out of 29

501 Patients Receiving at Least One Drug in Part D
93%Patients 65 Years and Older
63% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Arkansas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

11% of this provider’s 501 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

1% of this provider’s 11,335 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$51 was the average price of a prescription from this provider, compared to $52 among peers.

Prescriptions per Patient

24 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Arkansas
LEVOTHYROXINE SODIUM 723 689 1 1
SIMVASTATIN 589 533 2 4
FUROSEMIDE 480 422 3 3
LISINOPRIL 417 395 4 2
GABAPENTIN 405 378 5 10
AMLODIPINE BESYLATE 385 377 6 5
DONEPEZIL HCL 313 301 7 9
CITALOPRAM HBR 312 285 8 11
POTASSIUM CHLORIDE 298 278 9 6
OMEPRAZOLE 293 279 10 8
WARFARIN SODIUM 276 228 11 14
MIRTAZAPINE 258 248 12 13
HYDROCHLOROTHIAZIDE 217 213 13 20
NAMENDA 194 194 14 12
CARVEDILOL 178 164 15 27
METOPROLOL TARTRATE 175 169 16 15
HYDROCODONE-ACETAMINOPHEN 157 126 S3 17 7
TAMSULOSIN HCL 101 101 18 31
METOPROLOL SUCCINATE 98 94 19 16
EXELON 97 97 20 38
CYMBALTA 97 87 20 29
METFORMIN HCL 95 90 22 19
ATENOLOL 92 82 23 23
ZOLPIDEM TARTRATE 88 71 24 30
QUETIAPINE FUMARATE 84 75 25 32
CARBIDOPA-LEVODOPA 83 83 26 42
ESCITALOPRAM OXALATE 81 81 27 37
CLOPIDOGREL 80 73 28 33
RISPERIDONE 78 78 29 49
LANTUS 75 68 30 39
PANTOPRAZOLE SODIUM 73 72 31 59
HYDRALAZINE HCL 71 65 32 56
ALENDRONATE SODIUM 70 70 33 26
LANTUS SOLOSTAR 70 61 33 92
GLIPIZIDE 68 67 35 50
SERTRALINE HCL 67 67 36 17
LEVOFLOXACIN 66 63 37 60
PRAVASTATIN SODIUM 65 65 38 18
CLONIDINE HCL 64 64 39 53
DIGOXIN 63 61 40 34
DIOVAN 62 62 41 35
ISOSORBIDE MONONITRATE ER 62 53 41 44
GEMFIBROZIL 62 40 41 116
MELOXICAM 60 60 44 36
ALLOPURINOL 60 32 44 40
PLAVIX 59 57 46 51
SPIRIVA 57 57 47 96
SYNTHROID 54 54 48 52
BRIMONIDINE TARTRATE 52 52 49 201
VENLAFAXINE HCL 52 48 49 93
POLYETHYLENE GLYCOL 3350 51 49 51 46
CEPHALEXIN 51 47 51 89
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 18, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.